CEO of Pfizer Creates New Treatment Pill Projected to be Available by the End of 2021

CEO of Pfizer Creates New Treatment Pill Projected to be Available by the End of 2021

The Pfizer pill is described as a “game-changer.”

An oral pill is expected to treat variants of COVID-19. The CEO of Pfizer announced that an antiviral treatment for the disease could be available to the public by the end of 2021.

A news article in the UK says Pfizer is currently conducting trials in the U.S. and Belgium, where adult volunteers are taking pills to help find a “cure” for COVID-19. Pfizer CEO Albert Bourla said “it is accurate” to say the company is “working on” such therapies. The company is actually testing two antivirals, one that is injected and one that is taken orally.

Bourla explained Pfizer is focusing on the oral option because it provides multiple advantages, including people not coming to the hospital. He described the oral antiviral pill as a “game changer.” He says the end of the year is a reasonable time frame for availability to the public, all depending on the success of the trials and FDA approval.

Although it’s still new, Pfizer announced the beginning of Phase 1 clinical trials of the drug - PF-07321332 - in late March. An article says it’s designed to work by stopping SARS-CoV-2 from replicating in the cell.

"Tackling the Covid-19 pandemic requires both prevention via vaccine and targeted treatment for those who contract the virus," said Mikael Dolsten, Pfizer's chief scientific officer, "Given the way that SARS-CoV-2 is mutating and the continued global impact of COVID-19, it appears likely that it will be critical to have access to therapeutic options both now and beyond the pandemic."

More than 296 million* COVID-19 vaccines have been administered in the U.S. so far.

About the Author

Shereen Hashem is the Associate Content Editor for Occupational Health & Safety magazine.

Download Center

  • Safety Metrics Guide

    Is your company leveraging its safety data and analytics to maintain a safe workplace? With so much data available, where do you start? This downloadable guide will give you insight on helpful key performance indicators (KPIs) you should track for your safety program.

  • Job Hazard Analysis Guide

    This guide includes details on how to conduct a thorough Job Hazard Analysis, and it's based directly on an OSHA publication for conducting JHAs. Learn how to identify potential hazards associated with each task of a job and set controls to mitigate hazard risks.

  • A Guide to Practicing “New Safety”

    Learn from safety professionals from around the world as they share their perspectives on various “new views” of safety, including Safety Differently, Safety-II, No Safety, Human and Organizational Performance (HOP), Resilience Engineering, and more in this helpful guide.

  • Lone Worker Safety Guide

    As organizations digitalize and remote operations become more commonplace, the number of lone workers is on the rise. These employees are at increased risk for unaddressed workplace accidents or emergencies. This guide was created to help employers better understand common lone worker risks and solutions for lone worker risk mitigation and incident prevention.

  • EHS Software Buyer's Guide

    Learn the keys to staying organized, staying sharp, and staying one step ahead on all things safety. This buyer’s guide is designed for you to use in your search for the safety management solution that best suits your company’s needs.

  • Vector Solutions

OH&S Digital Edition

  • OHS Magazine Digital Edition - June 2022

    June 2022

    Featuring:

    • SAFETY CULTURE
      Corporate Safety Culture Is Workplace Culture
    • HEAT STRESS
      Keeping Workers Safe from Heat-Related Illnesses & Injuries
    • EMPLOYEE HEALTH SCREENING
      Should Employers Consider Oral Fluid Drug Testing?
    • PPE FOR WOMEN
      Addressing Physical Differences
    View This Issue